CYPHERPUNK TECHNOLOGIES INC. (CYPH) Current Ratio
- Current ratio · latest quarter: Value 79.19×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 79.19× | Current assets / current liabilities. $137.55M ÷ $1.74M ≈ 79.19× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 137.55M USD | Assets, Current |
| Current obligations | 1.74M USD | Liabilities, Current |
| Cash and equivalents | 7.62M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 588.00K USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $137.55M | $1.74M | $7.62M | (m) | (m) | (m) | $588.00K | (m) | 79.19× |
| 2026-03-31 | $81.92M | $3.00M | $6.69M | (m) | (m) | (m) | $516.00K | (m) | 27.28× |
| 2025-12-31 | $162.08M | $4.56M | $14.04M | (m) | (m) | (m) | $1.98M | (m) | 35.56× |
| 2025-09-30 | $10.50M | $8.70M | $9.69M | (m) | (m) | (m) | $4.28M | (m) | 1.21× |
| 2025-06-30 | $19.16M | $14.32M | $18.13M | (m) | (m) | (m) | $7.34M | (m) | 1.34× |
| 2025-03-31 | $33.87M | $14.04M | $32.71M | (m) | (m) | (m) | $6.36M | (m) | 2.41× |
| 2024-12-31 | $48.04M | $14.08M | $47.25M | (m) | (m) | (m) | $4.74M | (m) | 3.41× |
| 2024-09-30 | $63.81M | $16.09M | $62.82M | (m) | (m) | (m) | $5.95M | (m) | 3.97× |
| 2024-06-30 | $79.59M | $15.60M | $78.48M | (m) | (m) | (m) | $7.81M | (m) | 5.10× |
| 2024-03-31 | $56.19M | $10.44M | $54.92M | (m) | (m) | (m) | $5.95M | (m) | 5.38× |
| 2023-12-31 | $71.60M | $12.68M | $70.64M | (m) | (m) | (m) | $6.46M | (m) | 5.64× |
| 2023-09-30 | $81.76M | $11.04M | $80.74M | (m) | (m) | (m) | $5.90M | (m) | 7.41× |
| 2023-06-30 | $93.88M | $11.76M | $91.42M | (m) | (m) | (m) | $6.50M | (m) | 7.98× |
| 2023-03-31 | $104.70M | $10.31M | $102.04M | (m) | (m) | (m) | $5.50M | (m) | 10.15× |
| 2022-12-31 | $67.95M | $11.22M | $65.50M | (m) | (m) | (m) | $5.66M | (m) | 6.05× |
| 2022-09-30 | $79.94M | $11.72M | $78.31M | (m) | (m) | (m) | $6.28M | (m) | 6.82× |
| 2022-06-30 | $92.44M | $10.41M | $90.88M | (m) | (m) | (m) | $7.55M | (m) | 8.88× |
| 2022-03-31 | $104.94M | $7.34M | $103.22M | (m) | (m) | (m) | $4.29M | (m) | 14.29× |
| 2021-12-31 | $116.87M | $9.99M | $114.92M | (m) | (m) | (m) | $4.19M | (m) | 11.70× |
| 2021-09-30 | $125.10M | $11.26M | $124.77M | (m) | (m) | (m) | $7.97M | (m) | 11.11× |
| 2021-06-30 | $36.02M | $8.06M | $35.73M | (m) | (m) | (m) | $4.34M | (m) | 4.47× |
| 2021-03-31 | $43.78M | $7.39M | $43.49M | (m) | (m) | (m) | $3.51M | (m) | 5.92× |
| 2020-12-31 | $52.27M | $7.37M | $52.07M | (m) | (m) | (m) | $2.72M | (m) | 7.09× |
| 2020-09-30 | $58.40M | $6.71M | $57.98M | (m) | (m) | (m) | $2.55M | (m) | 8.70× |
| 2020-06-30 | $65.28M | $6.84M | $64.89M | (m) | (m) | (m) | $2.72M | (m) | 9.55× |
| 2020-03-31 | $25.98M | $9.20M | $25.46M | (m) | (m) | (m) | $4.93M | (m) | 2.82× |
| 2019-12-31 | $4.24M | $8.49M | $3.89M | (m) | (m) | (m) | $4.57M | (m) | 0.50× |
| 2019-09-30 | $11.02M | $7.93M | $10.06M | (m) | (m) | (m) | $4.89M | (m) | 1.39× |
| 2019-06-30 | $16.79M | $8.46M | $15.75M | (m) | (m) | (m) | $5.33M | (m) | 1.99× |
| 2019-03-31 | $22.71M | $8.19M | $21.71M | (m) | (m) | (m) | $3.30M | (m) | 2.77× |
| 2018-12-31 | $17.32M | $6.45M | $16.28M | (m) | (m) | (m) | $3.58M | (m) | 2.69× |
| 2018-09-30 | $24.38M | $6.05M | $23.25M | (m) | (m) | (m) | $4.15M | (m) | 4.03× |
| 2018-06-30 | $32.05M | $6.03M | $30.48M | (m) | (m) | (m) | $4.77M | (m) | 5.32× |
| 2018-03-31 | $36.66M | $5.84M | $35.38M | (m) | (m) | (m) | $4.13M | (m) | 6.27× |
| 2017-12-31 | $27.66M | $6.08M | $25.74M | (m) | (m) | (m) | $2.62M | (m) | 4.55× |
| 2017-09-30 | $16.50M | $5.99M | $14.20M | (m) | (m) | (m) | $2.60M | (m) | 2.75× |
| 2017-06-30 | $20.72M | $4.38M | $17.17M | (m) | (m) | (m) | $3.09M | (m) | 4.74× |
| 2017-03-31 | $27.29M | $4.61M | $23.80M | (m) | (m) | (m) | $2.79M | (m) | 5.92× |
| 2016-12-31 | $4.03M | $36.16M | $793.00K | (m) | (m) | (m) | $3.23M | (m) | 0.11× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |